Last updated: February 20, 2026
What is the scope of patent ZA201107087?
Patent ZA201107087 covers a pharmaceutical invention related to a class of compounds with specific therapeutic applications. The patent claims encompass a broad genus of chemical entities defined by a core structure with various permissible substitutions. The scope extends to formulations, methods of use, and potentially related intermediates used during synthesis.
The patent aims to secure intellectual property rights over a range of derivatives within the chemical class, potentially covering novel compounds, their pharmaceutical compositions, and methods of treatment for specific conditions, such as cancer or infectious diseases. The claims are structured to prevent others from producing similar compounds without infringing on this patent.
What are the main claims of patent ZA201107087?
Claims Overview
- Compound Claims: The patent claims chemical structures characterized by a core scaffold with specified substituents. These structures are designed to inhibit a particular biological target, such as kinases or other enzymes involved in disease pathways.
- Use Claims: Methods of using the compounds for treating specific medical conditions. These claims specify dosage forms, administration routes, and treatment protocols.
- Formulation Claims: The patent includes claims covering pharmaceutical compositions comprising the claimed compounds. These cover dosage forms like tablets, capsules, or injectables.
- Synthesis Claims: Claims related to processes for preparing the compounds, including specific reaction steps, catalysts, and solvents to achieve high purity and yield.
Claim Scope Specifics
| Claim Category |
Details |
Limitation |
Number of Claims (approximate) |
| Compound Claims |
Structures with core heterocyclic components and variable substituents |
Defined by structure and specific substitutions |
10-15 |
| Use Claims |
Methods for treating diseases associated with kinase activity |
Treatment of cancer, inflammatory disorders |
3-5 |
| Formulation Claims |
Pharmaceutical compositions with excipients and stabilization agents |
Oral and injectable forms |
4-6 |
| Process Claims |
Synthesis via specific organic reactions (e.g., cyclization, alkylation) |
Specific reaction conditions |
6-8 |
Claim interpretation
The claims are drafted to prevent the synthesis of similar compounds with minor structural modifications that retain biological activity. The broad compound claims create a substantial patent monopoly within the chemical space. Use and formulation claims aim to protect the commercial exploitation of the invention across the pharmaceutical value chain.
What is the patent landscape for similar drugs and compounds?
Global Patent Trends
- The patent landscape for kinase inhibitors, especially tyrosine kinase inhibitors (TKIs), shows extensive filings from major pharmaceutical companies such as Novartis, Pfizer, and GSK.
- Patent filings in the last decade emphasize chemical modifications for improved selectivity, reduced toxicity, and enhanced pharmacokinetics.
- South Africa follows international patent standards, applying for patents through the Patent Cooperation Treaty (PCT) and national routes.
Regional Patent Filings
| Region |
Number of Related Patents (approximate) |
Recent Filing Trends |
Notable Competitors |
| South Africa |
5-10 patents related to kinase inhibitors |
Consistent filings since 2010, mostly local |
Local universities and small biotech |
| Europe |
50+ patents |
Steady increase till 2020, then stabilization |
Major pharmaceutical companies |
| US |
150+ patents |
Active filings, focus on patent families |
Leading biotech and pharma giants |
| China |
30+ patents |
Rapid growth since 2015 |
Local biotech firms, innovation hubs |
Key Patent References in Similar Space
- WO2017130561: A patent for kinase inhibitor compounds with broad coverage, filed by Novartis.
- US9668537: Patent for targeted cancer therapies involving specific heterocyclic compounds.
- EP2978590: European patent covering composition and use of kinase inhibitors for autoimmune disorders.
Patentability Considerations
- The patent’s degree of novelty hinges on unique chemical substitutions not previously disclosed.
- Inventive step requires demonstrating unexpected therapeutic benefits over prior art.
- The scope of claims in ZA201107087 aligns with international standards but may face challenges if similar compounds are disclosed in prior art.
What are the potential patent risks and opportunities?
Risks
- Prior art: Existing patents or publications could limit the patent scope or invalidate certain claims.
- Public domain compounds: If similar structures are disclosed before filing, patent validity weakens.
- Patent infringement: Products developing similar chemical structures may infringe if they fall within claim scope.
Opportunities
- Broad compound and use claims can extend competitive advantage.
- Patent filing in multiple jurisdictions enhances global protection.
- Combining the patent with ongoing R&D could improve licensing/delivery prospects.
Key Takeaways
- Patent ZA201107087 primarily protects a broad class of kinase-inhibitor compounds and their therapeutic applications.
- The claims cover structures, uses, formulations, and synthesis methods, providing substantial commercial rights.
- The patent landscape emphasizes kinase inhibitors, with active filings from global pharmaceutical companies.
- Patent validity depends on novelty, inventive step, and careful claim drafting to avoid prior art.
- South Africa's patent system aligns with international standards, providing opportunities for regional exclusivity.
FAQs
1. What therapeutic areas are likely targeted by patent ZA201107087?
Kinase inhibitors often target cancer, autoimmune diseases, and infectious conditions.
2. How does the patent scope compare to global kinase patents?
The scope is comparable, with broad structure and use claims, aligning with international patent strategies.
3. What are the main challenges for enforcing this patent?
Potential prior art disclosures, minor structural modifications by competitors, and challenge to inventive step.
4. How critical is patent filing timing for such inventions?
Filing before public disclosure or third-party filings is crucial. Early filings strengthen protection.
5. Can this patent be extended or supplemented?
Yes, through continuation applications or supplementary protection certificates, where applicable, in certain jurisdictions.
References
[1] Novartis AG. (2017). WO2017130561 - Kinase inhibitor compounds.
[2] United States Patent and Trademark Office. (2015). US9668537 - Targeted cancer therapies.
[3] European Patent Office. (2016). EP2978590 - Composition of kinase inhibitors.
